Currently, lung organoids are primarily used in the treatment of pulmonary diseases such as idiopathic pulmonary fibrosis (IPF) and are increasingly pivotal in lung cancer research, particularly for elucidating lung cancer pathogenesis and conducting drug screening assays. The research focus on lung organoids has gradually shifted from investigations into culture mechanisms and pulmonary pathophysiological processes to studies involving regenerative medicine and translational medicine. These advancements are expected to emerge as novel clinical therapeutic modalities in the near future.
Yang et al. (Wed,) studied this question.